OMER Omeros Corporation Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

OMER [NASD]

Omeros Corporation

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-2.06	Insider Own	0.10%	Shs Outstand	54.51M	Perf Week	-19.69%
Market Cap	646.25M	Forward P/E	-	EPS next Y	-1.82	Insider Trans	-7.34%	Shs Float	48.25M	Perf Month	-15.02%
Income	-108.00M	PEG	-	EPS next Q	-0.56	Inst Own	52.50%	Short Float	26.61%	Perf Quarter	-31.51%
Sales	100.30M	P/S	6.44	EPS this Y	34.60%	Inst Trans	1.77%	Short Ratio	8.82	Perf Half Y	-3.40%
Book/sh	-2.96	P/B	-	EPS next Y	17.60%	ROA	-103.60%	Target Price	-	Perf Year	-41.18%
Cash/sh	0.26	P/C	40.14	EPS next 5Y	-	ROE	79.70%	52W Range	8.50 - 25.46	Perf YTD	-27.32%
Dividend	-	P/FCF	-	EPS past 5Y	5.10%	ROI	-121.90%	52W High	-59.78%	Beta	1.52
Dividend %	-	Quick Ratio	1.00	Sales past 5Y	190.70%	Gross Margin	98.90%	52W Low	20.47%	ATR	0.78
Employees	258	Current Ratio	1.00	Sales Q/Q	-49.60%	Oper. Margin	-85.90%	RSI (14)	37.86	Volatility	6.33% 7.02%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-107.40%	Profit Margin	-	Rel Volume	0.84	Prev Close	10.98
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	1.46M	Price	10.24
Recom	2.20	SMA20	-11.33%	SMA50	-21.27%	SMA200	-25.99%	Volume	1,214,002	Change	-6.74%

Aug-21-20

Reiterated

H.C. Wainwright

Buy

$34 → $32

Aug-14-20

Reiterated

Maxim Group

Buy

$25 → $20

May-06-19

Initiated

Cantor Fitzgerald

Overweight

$26

Jul-12-18

Initiated

Seaport Global Securities

Buy

$30

Mar-23-18

Downgrade

Wedbush

Outperform → Neutral

$47 → $19

Mar-05-18

Downgrade

Needham

Buy → Hold

Nov-08-17

Initiated

H.C. Wainwright

Buy

$30

May-11-17

Downgrade

Cantor Fitzgerald

Buy → Neutral

$21 → $15

Mar-17-17

Reiterated

Needham

Buy

$24 → $22

Mar-17-17

Reiterated

Maxim Group

Buy

$19 → $22

Nov-16-16

Reiterated

Wedbush

Outperform

$56 → $47

Nov-10-16

Reiterated

Needham

Buy

$28 → $24

Aug-10-16

Reiterated

Maxim Group

Buy

$30 → $19

Jun-03-16

Initiated

Cantor Fitzgerald

Buy

$21

Mar-02-16

Reiterated

Needham

Buy

$30 → $28

Feb-29-16

Reiterated

Wedbush

Outperform

$65 → $62

Nov-11-15

Reiterated

Needham

Buy

$32 → $30

Aug-18-15

Reiterated

WBB Securities

Strong Buy

$60 → $75

Aug-10-15

Initiated

ROTH Capital

Buy

$38

Mar-18-15

Reiterated

Needham

Buy

$22 → $32

Sep-14-20 02:10PM	Key Things To Understand About Omeros' (NASDAQ:OMER) CEO Pay Cheque Simply Wall St. +5.60%
Sep-11-20 07:00AM	Omeros to Present at the Cantor Virtual Global Healthcare Conference Business Wire
Sep-09-20 08:45AM	Omeros (OMER) Catches Eye: Stock Jumps 6% Zacks
Sep-03-20 09:38AM	Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 Patients Business Wire
Aug-31-20 08:18AM	How Does Omeros's Debt Look? Benzinga
08:00AM	Omeros Investigational New Drug Application for OMS906 Cleared by FDA Business Wire
Aug-12-20 12:35PM	Here's Why Omeros Fell Over 13% Today Motley Fool -13.97%
06:30AM	Omeros Announces Pricing of Public Offerings Business Wire
Aug-11-20 08:20AM	The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September Benzinga -25.47%
Aug-10-20 05:45PM	Omeros (OMER) Reports Q2 Loss, Lags Revenue Estimates Zacks +50.88%
04:12PM	Omeros Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes Business Wire
04:01PM	Omeros Corporation Reports Second Quarter 2020 Financial Results Business Wire
12:25PM	Dow Jones Leads, Nasdaq Lags As Market Weighs Trump Orders, China Tensions Investor's Business Daily
11:41AM	Omeros Rallies On COVID-19 Study Results: What You Should Know Benzinga
11:35AM	ROCE Insights For Omeros Benzinga
09:01AM	Omeros Reports Coronavirus Treatment Success; Stock Soars Investor's Business Daily
07:30AM	Omeros Corporation Reports Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19-Associated Acute Respiratory Distress Syndrome Business Wire
Aug-06-20 12:30PM	Analysts Estimate Omeros (OMER) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-26-20 06:27AM	Could This Obscure Biotech Stock Make You a Fortune? Motley Fool
Jul-15-20 03:06PM	Omeros'(NASDAQ:OMER) Share Price Is Down 35% Over The Past Three Years. Simply Wall St. +5.62%
Jun-24-20 04:27PM	Hedge Funds Are Buying Omeros Corporation (OMER) Insider Monkey
Jun-12-20 08:30AM	Omeros Narsoplimab Pivotal Trial Data Shared in Oral Presentation at Annual European Hematology Association Congress Business Wire
Jun-11-20 08:45AM	Omeros Narsoplimab Pivotal Trial Data to be Shared as an Oral Presentation at Annual European Hematology Association Congress Business Wire
Jun-08-20 02:28PM	Edited Transcript of OMER earnings conference call or presentation 11-May-20 8:30pm GMT Thomson Reuters StreetEvents +6.28%
May-26-20 06:45PM	Omeros Gets Technical Rating Upgrade, Relative Strength Line Moves Up To 75 Investor's Business Daily
May-14-20 09:00AM	Omeros Corporation Announces Presentation of Narsoplimab Pivotal Trial Data at Upcoming European Hematology Association Annual Congress Business Wire
May-12-20 06:01AM	Omeros (OMER) Q1 2020 Earnings Call Transcript Motley Fool -11.60%
May-11-20 06:55PM	Omeros (OMER) Reports Q1 Loss, Lags Revenue Estimates Zacks +6.15%
04:02PM	Omeros Corporation Reports First Quarter 2020 Financial Results Business Wire
May-08-20 08:36AM	Should You Buy Omeros (OMER) Ahead of Earnings? Zacks
May-05-20 07:00AM	Omeros Corporation to Announce First Quarter Financial Results on May 11, 2020 Business Wire
Mar-11-20 03:38PM	Edited Transcript of OMER earnings conference call or presentation 2-Mar-20 9:30pm GMT Thomson Reuters StreetEvents -8.74%
Mar-04-20 10:00AM	Company News for Mar 4, 2020 Zacks
Mar-02-20 05:35PM	Omeros (OMER) Reports Q4 Loss, Tops Revenue Estimates Zacks +5.71%
04:03PM	Omeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results Business Wire
04:01PM	Omeros Corporation Reports Updated Results from Narsoplimab HSCT-TMA Clinical Trial and Highlights from Recent Clinical and CMC Meetings with FDA Business Wire
Feb-24-20 07:00AM	Omeros Corporation to Announce Fourth Quarter and Year-End 2019 Financial Results on March 2, 2020 Business Wire
Feb-11-20 09:35AM	Is Omeros Corporation's (NASDAQ:OMER) CEO Salary Justified? Simply Wall St.
08:30AM	Omeros Corporation Appoints Former Amazon Treasurer Kurt Zumwalt to Board of Directors Business Wire
Feb-03-20 03:49PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER GlobeNewswire
Jan-23-20 05:30PM	Omeros seeks accelerated approval from FDA for new drug American City Business Journals
Dec-20-19 05:16PM	Hedge Funds Arent Crazy About Omeros Corporation (OMER) Anymore Insider Monkey
Dec-18-19 08:30AM	myTomorrows and Omeros Corporation Collaborate to Provide an Expanded Access Program for Narsoplimab Business Wire
Dec-16-19 08:30AM	Omeros Newly Presented GPR174 Immuno-oncology Data at ESMO Immuno-Oncology Congress Show Inhibition of Both Checkpoint and Tumor-Promoting Factors Business Wire
Dec-13-19 09:30AM	Omeros Announces Full Exercise and Closing of Underwriters Option to Purchase Additional Shares Business Wire
Dec-10-19 08:30AM	Omeros to Present GPR174 Data at the European Society for Medical Oncology 2019 Immuno-Oncology Congress in Geneva Business Wire
Dec-05-19 07:14AM	The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission Benzinga -12.66%
Dec-04-19 04:11PM	Omeros Announces Proposed Public Offering of Common Stock Business Wire +6.05%
10:42AM	Omeros Aces Late-Stage Trial Of Transplant Drug Narsoplimab Benzinga
10:38AM	Omeros stock gains on transplant drug data MarketWatch
07:00AM	Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Patients Treated with Narsoplimab Business Wire
Dec-03-19 11:45PM	Edited Transcript of OMER earnings conference call or presentation 12-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-20-19 08:45AM	Omeros New GPR174 Immuno-oncology Data Presented at the American Association for Cancer Research Conference In Boston Now Available Online Business Wire
Nov-19-19 08:45AM	Omeros Presents New GPR174 Immuno-oncology Data Today at the American Association for Cancer Research Conference in Boston Business Wire
Nov-16-19 08:10AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER ACCESSWIRE
Nov-13-19 02:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER ACCESSWIRE
09:59AM	What Kind Of Shareholder Appears On The Omeros Corporation's (NASDAQ:OMER) Shareholder Register? Simply Wall St.
Nov-12-19 05:35PM	Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:02PM	Omeros Corporation Reports Third Quarter 2019 Financial Results Business Wire
Nov-11-19 05:16PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER GlobeNewswire
Nov-08-19 08:30AM	Omeros to Present GPR174 Data at Upcoming American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy Business Wire
Nov-07-19 05:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER ACCESSWIRE
08:30AM	Omeros Scientists Win 2019 Prix Galien Research Award Business Wire
Nov-06-19 08:15AM	Omeros Corporation to Announce Third Quarter 2019 Financial Results on November 12, 2019 Business Wire
Nov-04-19 03:00PM	Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Omeros Corporation (OMER) ACCESSWIRE -16.10%
02:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER GlobeNewswire
07:50AM	Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain Business Wire
Nov-01-19 11:22AM	Were Hedge Funds Right About Warming Up To Omeros Corporation (OMER)? Insider Monkey
Oct-29-19 09:00AM	Omeros Narsoplimab Receives Positive Opinion from European Medicines Agency for Pediatric Investigation Plan Required for MAA Submission Business Wire
Oct-28-19 08:45AM	Omeros Corporation Initiates BLA Submission for Narsoplimab for the Treatment of HSCT-TMA Business Wire +6.15%
Oct-21-19 09:46AM	Here's Why You Should Hold on to Chemed (CHE) Stock Right Now Zacks
Oct-18-19 04:31AM	2 Candidates That Could Be the Next Biotech Rockets TheStreet.com
Oct-01-19 08:30AM	Product-Specific J-Code for Omeros OMIDRIA® is Now in Effect Business Wire
Sep-25-19 09:01PM	Edited Transcript of OMER earnings conference call or presentation 8-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
08:45AM	Omeros Announces Publication of Study Showing that Inhibition of MASP-2, the Key Enzyme of the Complement Systems Lectin Pathway, Protects Against Renal Injury Caused by Proteinuria Business Wire
Sep-16-19 08:45AM	Omeros Corporation Announces Positive Results from Phase 1 Study of its Lead PDE7 Inhibitor in Development for Addiction Business Wire
Sep-11-19 08:45AM	FDA Confirms Omeros Schedule for Rolling Review of the Companys BLA for Narsoplimab in the Treatment of HSCT-TMA Business Wire
Sep-10-19 10:01AM	Omeros (NASDAQ:OMER) Is Carrying A Fair Bit Of Debt Simply Wall St.
08:30AM	Omeros Discovers New Cancer-Immunity Pathways Controlled by GPR174 Business Wire
Sep-06-19 07:00AM	Omeros to Present at the H.C. Wainwright 21st Annual Global Investment Conference Business Wire
Aug-22-19 10:58AM	How Medical Billing Coverage Spells Success Or Failure For Drugmakers Motley Fool
Aug-09-19 08:30AM	Omeros to Present at the 2019 Wedbush PacGrow Healthcare Conference Business Wire +11.89%
04:23AM	Omeros (OMER) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 06:20PM	Omeros (OMER) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:02PM	Omeros Corporation Reports Second Quarter 2019 Financial Results Business Wire
Aug-05-19 04:02PM	Omeros Corporation to Announce Second Quarter 2019 Financial Results on August 8, 2019 Business Wire
Aug-01-19 10:32AM	Will Omeros (OMER) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-31-19 08:30AM	Omeros and Lonza Enter Long-Term Manufacturing Agreement for Commercial Supply of Narsoplimab Business Wire
Jul-26-19 10:33AM	The Omeros (NASDAQ:OMER) Share Price Has Gained 31% And Shareholders Are Hoping For More Simply Wall St.
Jul-24-19 08:45AM	Omeros OMIDRIA® Receives Product-Specific J-Code from CMS Business Wire
Jul-11-19 02:46PM	Calls Pop as Drug Stock Gets FDA Boost Schaeffer's Investment Research
10:23AM	Omeros, FDA Agree On Endpoint For Pivotal Trial Of Small Blood Vessel Damage Treatment Benzinga
08:00AM	Omeros Announces Agreement with FDA on Primary Endpoint for Narsoplimab BLA in Stem Cell Transplant-Associated TMA Business Wire
Jun-14-19 11:38AM	Edited Transcript of OMER earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
Jun-05-19 08:30AM	Omeros Corporation Announces Assignment of Rapporteurs for European Marketing Authorization Application for Narsoplimab for Treatment of HSCT-TMA Business Wire
May-29-19 12:34PM	Is Omeros Corporation's (NASDAQ:OMER) CEO Paid At A Competitive Rate? Simply Wall St.
May-15-19 07:00AM	Omeros to Present at the UBS Global Healthcare Conference Business Wire
May-11-19 03:23PM	Omeros (OMER) Q1 2019 Earnings Call Transcript Motley Fool
May-09-19 06:25PM	Omeros (OMER) Reports Q1 Loss, Lags Revenue Estimates Zacks
05:13PM	Omeros: 1Q Earnings Snapshot Associated Press

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that is in Phase III clinical trial for hematopoietic stem-cell transplant-associated thrombotic microangiopath, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consists of PPAR? (OMS405) that is in Phase II clinical trial to treat opioid and nicotine addiction; and PDE7 (OMS527), which is in Phase I clinical trial for treating addiction and compulsive disorders, and movement disorders. In addition, the company's preclinical programs comprise MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders; MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Further, its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular (CV), musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cable Thomas J.	Director	May 13	Option Exercise	5.92	5,000	29,600	40,067	May 15 08:00 PM
Cable Thomas J.	Director	May 13	Sale	14.40	5,000	71,999	35,067	May 15 08:00 PM
Hood Leroy E. MD PhD	Director	Mar 13	Option Exercise	5.92	5,000	29,600	69,390	Mar 17 05:25 PM
Demopulos Peter A MD	Director	Dec 14	Option Exercise	7.56	3,334	25,205	188,516	Dec 17 09:40 PM
Hood Leroy E. MD PhD	Director	Dec 14	Option Exercise	7.56	10,000	75,600	64,390	Dec 17 09:40 PM
Cable Thomas J.	Director	Dec 03	Option Exercise	7.56	10,000	75,600	45,067	Dec 05 09:15 PM
Cable Thomas J.	Director	Dec 03	Sale	14.41	10,000	144,148	35,067	Dec 05 09:15 PM
Cable Thomas J.	Director	Oct 14	Sale	15.12	5,000	75,590	35,067	Oct 16 08:36 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience